Femasys Inc. (FEMY)
FEMYNASDAQ-CMMedical/Dental Instruments
$1.43
+0.0100 (+0.70%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $11.98m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.26 to $22.20
- Average volume
- 95.1k
- Previous close
- $1.42
Analysts
2 coveringStrong Buy2 buy, 0 hold, 0 sell
Targets a year out average $10.00, +599.3% from here
Earnings
Next report Nov 13, 2026
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $729.0k | $813.0k | $425.0k | $332.0k |
| Gross profit | $436.0k | $510.0k | $266.0k | $189.0k |
| Operating income | -$3.65m | -$4.62m | -$4.22m | -$5.07m |
| Net income | -$4.20m | -$3.95m | $846.0k | -$4.47m |
Last four quarters: revenue $2.30m, margin -511.9%, free cash flow -$18.07m
News
8 latest- Biotech Stocks Move Higher: MBRX Gains 15%, FEMY Rises 7%, RVMD Advances 7%, MYGN Surges Over 40% RTTNews · Oct 20, 2026
- Femasys Taps SandsRx Pharmacy To Coordinate Medications For FemaSeed Patients; Stock Up RTTNews · Oct 20, 2026
- Femasys Doubles Enrollment Sites For FemBloc Pivotal Study; Stock Down RTTNews · Oct 14, 2026
- Femasys Expands Fertility Portfolio Adoption Through Minnesota Women's Care RTTNews · Sep 15, 2026
- Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials RTTNews · Sep 11, 2026
- Femasys Partners With CapexMD To Expand Access To FemaSeed Fertility Portfolio RTTNews · Sep 9, 2026
- Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal RTTNews · Aug 28, 2026
- Femasys Partners With UNC Health To Expand Fertility Care Access RTTNews · Aug 26, 2026
The company
Femasys is a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide. The Company is focused on commercializing its fertility portfolio, led by FemaSeed Intratubal Insemination, together with complementary diagnostic and sperm preparation products, in the U.S. and key international markets. Femasys is also advancing FemBloc, its non-surgical, in-office permanent birth control solution, toward U.S. FDA approval through the ongoing FINALE pivotal trial (NCT05977751). FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025, supporting commercialization through strategic partnerships in select international markets.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- femasys.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.